Concepedia

Author

Yvonne Lassere

The University of Texas MD Anderson Cancer Center

Also Known As

Y Lassere, Y. Lassere, Y. M. Lassere, Yvonne Lassere

24

Publications

1.1K

Citations

14

H-Index

24

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterTaiho Pharmaceutical (Japan)
YL

About

Yvonne Lassere is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

313

2

Pharmacology

5

5

248

3

Pathology

2

2

65

4

Gastroenterology

1

1

10

5

Surgical Oncology

1

1

10

Yvonne Lassere

×

14

Publications

902

Citations

12

H-Index

YearCitations

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.

Richard Pazdur, Yvonne Lassere, Verna A. Rhodes,

Journal of Clinical Oncology

1994

206

Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.

D H Ho, Richard Pazdur, W Covington,

PubMed

1998

124

Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.

Paulo M. Hoff, Everardo D. Saad, Jaffer A. Ajani,

PubMed

2003

97

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors

David S. Hong, James L. Abbruzzese, K. R. Bogaard,

Cancer

2006

86

Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer

Paulo M. Hoff, Nora A. Janjan, Everardo D. Saad,

Journal of Clinical Oncology

2000

62

Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal Carcinoma

Paulo M. Hoff, Richard Pazdur, Yvonne Lassere,

Journal of Clinical Oncology

2004

59

Phase II trial of docetaxel (Taxotere®) in metastatic colorectal carcinoma

Richard Pazdur, Yvonne Lassere, Lay-Tin Soh,

Annals of Oncology

1994

55

Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules

Richard Pazdur, Yvonne Lassere, Enrique Díaz-Cantón,

Anti-Cancer Drugs

1996

53

Phase I Trial ofU racil-Tegafur (UFT) plus Oral Leucovorin: 28-Day Schedule

Richard Pazdur, Yvonne Lassere, Enrique Díaz-Cantón,

Cancer Investigation

1998

40

Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog

Melanie Royce, Paulo M. Hoff, Pamela Dumas,

Journal of Clinical Oncology

2001

39

Page 1